# Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

> **NCT01324583** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel (XRP6258)
- **DRUG:** prednisolone

## Key facts

- **NCT ID:** NCT01324583
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324583, "Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01324583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*